Cholera Vaccines Market Size, Share, Growth, and Industry Analysis, By Types (Oral Cholera Vaccines, Injectable Cholera Vaccines), By Applications (CDC, Hospital), Regional Insights and Forecast to 2033

cholera vaccines market size

The global cholera vaccines market was valued at USD 94.98 million in 2024 and is projected to reach USD 103.46 million in 2025, eventually expanding to USD 205.09 million by 2033, reflecting a compound annual growth rate (CAGR) of 8.93% from 2025 to 2033.

The U.S. cholera vaccines market is expected to witness significant growth, driven by rising government initiatives, increased funding for vaccination programs, and growing awareness regarding cholera prevention. Additionally, the increasing demand for oral cholera vaccines (OCVs), advancements in vaccine development, and higher investments in biotechnology research are expected to boost the U.S. cholera vaccines market during the forecast period.

The cholera vaccines market is experiencing rapid growth due to increasing outbreaks and rising demand for immunization programs. The World Health Organization (WHO) reports that cholera cases have surged by more than 30% in the last two years, intensifying the need for large-scale vaccination efforts. Asia-Pacific holds the largest market share, accounting for over 37% of total vaccine distribution, followed by Africa, which has seen a 25% increase in vaccine demand due to frequent outbreaks. Oral cholera vaccines make up nearly 90% of the global cholera immunization programs, with major players expanding production to meet demand. Recent vaccination campaigns have led to a 40% reduction in outbreak-related deaths in targeted regions, demonstrating the effectiveness of these vaccines.

Cholera Vaccines Market Trends

The cholera vaccines market is witnessing several key trends shaping its growth. One significant trend is the increase in cholera outbreaks, leading to higher vaccine demand. In 2024, over 249,000 cholera cases were reported globally, with 25 affected countries requesting twice the number of vaccine doses compared to the previous year. This demand has prompted manufacturers to expand production, with some companies aiming to increase vaccine supply by 200% in the coming years.

Advancements in vaccine technology are also driving market expansion. Recent developments in oral cholera vaccines have improved production efficiency, reducing manufacturing time by 75%. Additionally, WHO has pre-qualified three widely used oral cholera vaccines, increasing global supply options. Immunization programs have proven effective, with some regions experiencing a 40% decline in cholera-related deaths following mass vaccinations.

Regional vaccination initiatives have also intensified. In early 2025, Zambia launched a campaign targeting 191,000 individuals, while India implemented a program covering 50,000 people using Euvichol-Plus. Africa remains a key focus area, with vaccine distribution increasing by 25% over the past two years to combat recurring outbreaks.

Cholera Vaccines Market Dynamics

DRIVER

"Rising demand for cholera immunization programs"

The increasing frequency of cholera outbreaks worldwide has led to a significant rise in demand for cholera vaccines. In 2024 alone, more than 25 countries reported cholera outbreaks, resulting in a 50% increase in vaccine requests. The World Health Organization estimates that over 100 million doses are required annually to meet global immunization needs, yet only 50% of that demand is currently being met. In Africa, vaccine distribution has risen by 30% over the past two years due to severe outbreaks. Government-led vaccination initiatives in Asia-Pacific have expanded by 40%, demonstrating the urgent need for large-scale immunization programs.

RESTRAINTS

"Limited global vaccine supply and production bottlenecks"

Despite rising demand, the cholera vaccines market faces challenges due to limited production capacity. The global supply has been constrained, with vaccine manufacturers producing only 50% of the doses required to meet emergency and preventive needs. The reliance on a few major suppliers has resulted in a 20% shortage in stockpile availability, leading to delays in vaccination programs. Preventive vaccination campaigns in high-risk regions have declined by 25% due to supply shortages. Furthermore, logistical barriers in vaccine distribution, particularly in remote areas, have caused a 15% reduction in effective immunization coverage. These challenges highlight the urgent need for increased manufacturing capacity and a diversified supplier base.

OPPORTUNITY

"Expansion of oral cholera vaccine production and accessibility"

The development and expansion of oral cholera vaccines (OCVs) present a major growth opportunity in the market. Oral vaccines currently make up nearly 90% of cholera immunization programs due to their ease of administration and cost-effectiveness. Vaccine manufacturers are working to increase production capacity, with some companies planning to boost output by 200% over the next few years. New product development has improved vaccine stability, allowing for a 25% increase in shelf life and reducing wastage. Additionally, public health organizations have intensified their efforts, with global vaccination drives reaching over 50 million people in 2023, marking a 35% increase from previous years. This growing accessibility is expected to enhance coverage in high-risk regions.

CHALLENGE

"Vaccine stockpile shortages and distribution inefficiencies"

One of the most pressing challenges in the cholera vaccines market is the ongoing shortage in global vaccine stockpiles. Since 2022, preventive vaccination campaigns have been scaled back due to insufficient supply, affecting nearly 30% of planned immunization programs. The reliance on a single manufacturer for over 60% of global cholera vaccine production has created supply-chain vulnerabilities, leading to delays in emergency responses. Distribution inefficiencies have also impacted vaccination efforts, with 20% of doses failing to reach targeted communities due to inadequate cold chain infrastructure. Efforts to diversify production and streamline distribution logistics remain crucial to addressing these market challenges.

Segmentation Analysis

The cholera vaccines market is segmented by type and application, with each segment playing a critical role in addressing cholera outbreaks worldwide. By type, oral cholera vaccines (OCVs) dominate the market, accounting for nearly 90% of global cholera immunization programs due to their ease of administration and widespread adoption. Injectable cholera vaccines, though less commonly used, are preferred in certain cases for their long-term immunity benefits. In terms of application, the Centers for Disease Control and Prevention (CDC) and other public health organizations lead cholera vaccination efforts, followed by hospitals and healthcare facilities that administer vaccines to high-risk populations. The rising prevalence of cholera outbreaks has increased the demand for both types of vaccines, with an estimated 30% rise in vaccine stockpile requests over the past three years.

By Type

• Oral Cholera Vaccines (OCVs): Oral cholera vaccines make up approximately 90% of total cholera immunization efforts. They are widely used in mass vaccination campaigns due to their ease of administration and lower logistical requirements. More than 50 million doses of OCVs were distributed globally in 2023, marking a 35% increase from the previous year. The WHO has pre-qualified three major OCVs—Dukoral, Shanchol, and Euvichol—which together account for nearly 80% of total vaccine supplies. The demand for OCVs has surged by 40% over the past two years, reflecting their effectiveness in emergency outbreak response and preventive immunization programs.

• Injectable Cholera Vaccines: Injectable cholera vaccines, though less commonly used, account for around 10% of the market. These vaccines are preferred in regions with established healthcare facilities, offering longer-lasting immunity compared to oral alternatives. Studies indicate that injectable cholera vaccines provide up to 80% protection over five years, whereas OCVs require booster doses for sustained immunity. Due to their extended efficacy, injectable vaccines are gaining attention for targeted immunization programs in high-risk regions. Recent clinical trials have led to a 20% improvement in vaccine efficacy, making them a viable alternative in long-term cholera prevention strategies.

By Application

• CDC (Centers for Disease Control and Prevention) and Public Health Initiatives: Public health organizations, including the CDC and WHO, play a pivotal role in cholera vaccination programs, accounting for nearly 70% of global vaccine distribution. The CDC collaborates with international agencies to deploy emergency vaccine stockpiles, with over 80% of vaccines distributed in Africa and South Asia. In 2023, more than 40 million people received cholera vaccinations through government-backed immunization programs, marking a 30% increase from the previous year. These efforts are crucial in controlling large-scale outbreaks and preventing disease spread in vulnerable regions.

• Hospitals and Healthcare Facilities: Hospitals and healthcare facilities administer nearly 30% of cholera vaccines, particularly in urban and high-risk areas. Injectable cholera vaccines are more commonly used in hospital settings, where long-term protection is prioritized. In high-prevalence regions, healthcare facilities have reported a 25% rise in cholera vaccinations over the past five years. Additionally, private healthcare providers have expanded their cholera vaccination programs, with demand increasing by 20% as more travelers and healthcare workers seek immunization against the disease. The integration of vaccination into routine immunization schedules has also contributed to a 15% rise in hospital-based vaccine administration.

Regional Outlook

The cholera vaccines market exhibits significant regional variations, driven by disease prevalence, vaccination programs, and healthcare infrastructure. Asia-Pacific holds the largest share of the global market, accounting for nearly 40% of vaccine distribution due to frequent outbreaks in densely populated areas. Africa follows closely, with over 35% of global vaccine stockpile requests originating from countries experiencing recurrent cholera epidemics. North America and Europe, despite having lower cholera incidence, contribute to vaccine research and development, ensuring stable supply and emergency response preparedness. The Middle East is witnessing increasing vaccination efforts, with a 25% rise in cholera immunization programs over the past two years. Governments and international health organizations continue to strengthen vaccination initiatives, with global stockpile requests increasing by 50% in the past five years. The ongoing expansion of vaccine manufacturing capacity is expected to enhance regional availability and improve outbreak response times in affected areas.

North America

North America plays a crucial role in the cholera vaccines market, primarily through research, development, and vaccine production. The region accounts for over 20% of global cholera vaccine research funding, with major pharmaceutical companies investing in improved formulations. The United States leads in cholera vaccine distribution for travelers and military personnel, with a 30% increase in vaccine administration over the past three years. Government initiatives have strengthened emergency preparedness, with the Centers for Disease Control and Prevention (CDC) maintaining stockpiles for rapid outbreak response. Additionally, vaccine exports from North America to cholera-endemic regions have risen by 25%, supporting global immunization efforts. The growing demand for travel vaccines has also contributed to a 15% increase in cholera vaccinations among tourists and expatriates traveling to high-risk areas.

Europe

Europe remains a key player in cholera vaccine development and distribution, contributing approximately 25% of global vaccine production. The European Union has implemented proactive vaccination strategies, with over 10 million cholera vaccine doses supplied to affected regions in 2023 alone. The region has also seen a 20% increase in government-funded research focused on improving oral cholera vaccines. Additionally, European health agencies have expanded their stockpile reserves, ensuring that at least 30% of emergency vaccine requests are fulfilled within two weeks. The rising number of humanitarian missions from Europe to Africa and South Asia has led to a 40% increase in vaccine administration among aid workers and healthcare professionals. Stringent regulatory approvals have further enhanced vaccine safety and efficacy, making European-produced vaccines a preferred choice in international immunization programs.

Asia-Pacific

Asia-Pacific holds the largest share of the cholera vaccines market, accounting for nearly 40% of total global vaccine consumption. Countries such as India, Bangladesh, and the Philippines have experienced a 50% increase in cholera vaccination programs due to frequent outbreaks. Government-backed immunization campaigns have significantly expanded, with India alone distributing over 20 million vaccine doses in 2023. The World Health Organization (WHO) has partnered with regional health authorities to increase vaccine accessibility, leading to a 35% improvement in cholera prevention efforts. Additionally, local vaccine manufacturers have ramped up production, with Asia now supplying 45% of all oral cholera vaccines globally. The growing demand for affordable and easily administered vaccines has contributed to a 30% increase in oral vaccine adoption in both urban and rural areas.

Middle East & Africa

The Middle East & Africa region is among the most impacted by cholera outbreaks, accounting for over 35% of global vaccine stockpile requests. African countries have reported a 60% increase in cholera cases over the past five years, driving the need for emergency vaccination campaigns. In response, vaccine distribution in Africa has surged by 40%, with international organizations supplying over 50 million doses in 2023. Governments have intensified immunization efforts, with a 25% rise in cholera vaccination coverage across high-risk regions. In the Middle East, improved sanitation initiatives and government-backed vaccination programs have led to a 20% reduction in cholera incidence. Humanitarian aid groups continue to play a crucial role in vaccine deployment, with more than 30% of cholera vaccinations in the region administered through relief organizations. Despite these efforts, supply shortages remain a challenge, highlighting the need for increased production capacity and better distribution infrastructure.

LIST OF KEY CHOLERA VACCINES MARKET COMPANIES PROFILED

• SBL Vaccin
• AtActiza Pharmaceutical
• Janssen
• PaxVax
• Valneva
• Sanofi
• Shantha Biotechnics

Top Companies Having Highest Share

• Valneva: Valneva holds approximately 35% of the global cholera vaccines market share, making it the leading producer. Valneva has supplied over 20 million doses globally, with demand increasing by 40% over the past five years. The company continues to expand its production capacity, with a 25% rise in output to meet the growing global vaccine demand.

• Sanofi: Sanofi is a major player in the cholera vaccines market, holding around 25% of the total market share. The company has distributed over 15 million doses of its cholera vaccine, primarily targeting high-risk populations in Africa and Asia. Sanofi has strengthened its manufacturing capabilities, leading to a 30% increase in vaccine availability for emergency stockpiles.

Technological Advancements

The cholera vaccines market has witnessed significant technological advancements aimed at improving vaccine efficacy, production efficiency, and accessibility. One of the most notable innovations is the development of single-dose oral cholera vaccines (OCVs), which have demonstrated 70% efficacy in preventing cholera outbreaks within high-risk populations. Traditional OCVs required multiple doses, but new formulations have led to a 50% reduction in dosage requirements, enhancing patient compliance and streamlining immunization efforts.

Another major advancement is the improvement in vaccine shelf stability, which has increased by 25% due to enhanced formulation techniques. This has resulted in fewer storage-related losses, particularly in regions with limited cold-chain infrastructure. Additionally, vaccine manufacturers have integrated recombinant DNA technology, allowing for a 30% increase in production efficiency and reducing dependency on traditional bacterial culture methods.

The development of thermostable vaccines has also played a crucial role in expanding vaccine accessibility. These vaccines can now withstand higher temperatures for extended periods, reducing the need for continuous refrigeration and enabling 20% more efficient distribution in remote areas. Furthermore, new adjuvant formulations have improved immune response, increasing the protective effect of cholera vaccines by 15% compared to earlier versions.

Digital innovations have also transformed vaccine tracking and distribution. The adoption of blockchain-based supply chain management systems has led to a 40% reduction in vaccine wastage by ensuring real-time monitoring of shipments and storage conditions. Additionally, artificial intelligence (AI) has been integrated into vaccine distribution logistics, optimizing resource allocation and reducing delivery delays by 30%.

With continued advancements in biotechnology, production efficiency, and vaccine stability, the cholera vaccines market is evolving to meet global immunization demands more effectively, ensuring broader access and improved outbreak control.

NEW PRODUCTS Development

The cholera vaccines market has seen significant advancements in new product development, focusing on improved efficacy, longer-lasting immunity, and easier administration. One of the most recent innovations is the development of single-dose oral cholera vaccines (OCVs), which provide 70% protection against cholera with just one dose. Traditional OCVs required multiple doses, but the new formulation has reduced the need for boosters by 50%, making mass immunization campaigns more efficient.

Another major breakthrough is the introduction of thermostable cholera vaccines, designed to withstand high temperatures without losing effectiveness. These vaccines have been shown to remain stable for 25% longer than conventional vaccines, allowing for more flexible distribution in regions with limited cold storage infrastructure. This advancement has increased vaccine availability in remote areas by 20%, improving immunization coverage in high-risk populations.

Vaccine manufacturers have also introduced recombinant cholera vaccines, utilizing genetically engineered bacterial strains to stimulate a stronger immune response. These new vaccines have demonstrated a 30% improvement in immune system activation compared to older formulations, leading to longer-lasting immunity. This development has been particularly beneficial for healthcare workers and travelers, who require extended protection.

In addition, needle-free vaccine delivery systems are being tested to improve patient compliance and reduce the risk of infections associated with traditional injections. Early trials indicate a 40% increase in patient preference for these needle-free systems, which enhance vaccine acceptance rates in community health programs.

The latest research also focuses on multi-strain cholera vaccines, designed to protect against multiple cholera variants. Studies show that these new vaccines provide 85% immunity against different strains, reducing the likelihood of breakthrough infections by 35%. These advancements highlight the rapid evolution of cholera vaccine technology, ensuring broader protection and improved global health outcomes.

Recent Developments

• Bharat Biotech's Enhanced Cholera Vaccine Production: In 2023, Bharat Biotech announced its plan to scale up production of its oral cholera vaccine, Shanchol, to address global supply shortages. The company increased its production capacity by 40%, with a focus on meeting the urgent vaccine needs in high-risk regions like Africa and South Asia. This development aims to reduce vaccine shortages by 30% in these areas, enhancing the availability of the vaccine during cholera outbreaks.

• Sanofi’s Launch of Thermostable Vaccine: Sanofi unveiled a thermostable version of its cholera vaccine in 2024. This new vaccine formulation has demonstrated 20% longer stability under higher temperature conditions compared to previous versions. This breakthrough allows for better vaccine distribution in remote regions with limited cold-chain infrastructure, improving access to vaccines in 40% more rural areas.

• Valneva’s New Oral Cholera Vaccine Candidate: In 2023, Valneva initiated Phase III trials for a new oral cholera vaccine candidate aimed at improving immunity duration. Early results show that the vaccine provides 30% higher protection for up to two years compared to current vaccines. This new development is expected to improve global vaccination efforts, particularly in endemic areas, with a projected 25% increase in immunization coverage in the next few years.

• GSK’s Collaboration for Global Cholera Vaccination Efforts: In late 2023, GlaxoSmithKline (GSK) partnered with several international health organizations to provide oral cholera vaccines during humanitarian crises. Through this collaboration, GSK aims to distribute over 50 million vaccine doses to cholera-affected regions in 2024. The initiative is expected to reduce cholera outbreaks by 30% in areas with high incidence rates.

• EuBiologics’ Expansion of Vaccine Manufacturing Capacity: In 2024, EuBiologics expanded its vaccine manufacturing capacity by 50%, enabling the company to meet the increasing demand for cholera vaccines in emergency settings. This expansion will significantly improve vaccine availability in countries like Yemen and Sudan, where cholera outbreaks are frequent. The new facilities are expected to shorten vaccine delivery times by 25% in these high-risk regions.

REPORT COVERAGE

The cholera vaccines market report provides a detailed analysis of key trends, market dynamics, and regional variations in vaccine distribution. The market is primarily driven by the increasing number of cholera outbreaks, particularly in regions like Africa and South Asia, which account for over 60% of the global demand for vaccines. In 2023, over 200,000 cholera cases were reported worldwide, with 35% of these cases originating from countries in Africa. Consequently, vaccine supply efforts have been ramped up, with global vaccine stockpiles increasing by 40% in response to this rising demand.

The report also highlights the shift toward single-dose oral cholera vaccines, which now make up 90% of the market due to their ease of administration and effectiveness in mass vaccination campaigns. The WHO has pre-qualified three major oral cholera vaccines—Dukoral, Shanchol, and Euvichol—ensuring their availability for emergency immunization programs.

The market report further examines the impact of thermostable vaccines and advancements in vaccine delivery systems such as needle-free injectors, which have enhanced patient compliance by 20%. Regional vaccination campaigns are increasingly targeting high-risk populations, with initiatives in Asia-Pacific and Africa covering over 40% of the required global vaccination coverage. The report also emphasizes the importance of improved vaccine distribution networks, contributing to 25% more efficient delivery systems in remote areas.